GABA THERAPEUTICS
GABA Therapeutics is developing GRX-917, an anxiety medication. The drug’s dual mechanism of action may also benefit a broad range of neuropsychiatric and neurological disorders.
GABA THERAPEUTICS
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.gabarx.com
Total Employee:
11+
Status:
Active
Contact:
(855) 277-3477
Total Funding:
15.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Wordpress Plugins
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Employees Featured
Founder
Key Employee Changes
| Date | New article |
|---|---|
| 2022-04-07 | GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as CEO and CMO |
Official Site Inspections
http://www.gabarx.com Semrush global rank: 5.87 M Semrush visits lastest month: 1.41 K
- Host name: 104.21.41.51
- IP address: 104.21.41.51
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Gaba Therapeutics"
About Us - gabarx.com
ABOUT US GABA Therapeutics is developing GRX-917, its lead drug candidate, across a broad range of therapeutic indications. The drug activates the production of brain neurosteroids …See details»
Gaba Therapeutics - Crunchbase Company Profile
GABA Therapeutics is developing GRX-917, an anxiety medication. The drug’s dual mechanism of action may also benefit a broad range of neuropsychiatric …See details»
Executive Team - gabarx.com
EXECUTIVE TEAM Mario Saltarelli, M.D., Ph.D. - Chief Executive Officer / Chief Medical Officer Dr. Saltarelli has over 25 years of experience in the biopharmaceutical industry, primarily in …See details»
atai Life Sciences Company GABA Therapeutics Announces …
Jan 9, 2023 “According to a World Health Organization report, the number of people living with anxiety disorders globally grew from 298 million people in 2020 to 374 million in 2021,” said …See details»
Gaba Therapeutics - Overview, News & Similar companies
Apr 7, 2022 Gaba Therapeutics contact info: Phone number: (949) 231-2244 Website: www.gabarx.com What does Gaba Therapeutics do? GABA Therapeutics, Inc is focused on …See details»
Gaba Therapeutics Company Profile | Management and Employees …
Www.gabarx.com . Gaba Therapeutics Profile and History. GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal …See details»
GABA Therapeutics, Inc Overview | SignalHire Company Profile
Organization Website: gabarx.com : Phone Number (855) 277-3477: GABA Therapeutics, Inc industries Biotech: Headquarters Location: 5000 Birch St, Newport Beach, California, 92660 …See details»
GABA Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Nov 1, 2024 www.gabarx.com. Startups | Subsidiary Company | 2018 | California, United States | 10-50 | www.gabarx.com. Last update 01 Nov 2024. Overview. ... panic disorder, and …See details»
GABA Therapeutics and ATAI Life Sciences Partner to Develop a …
Sep 20, 2019 GRX-917 has the potential to become front-line therapy for anxiety and has composition-of-matter patent protection until 2036. Moreover, preclinical studies using …See details»
GABA Therapeutics - PitchBook
GABA Therapeutics General Information Description. Developer of a medicinal compound intended to be used in the treatment of anxiety, depression, and a broad range of neurological disorders.See details»
BOARD OF DIRECTORS - gabarx.com
BOARD OF DIRECTORS H. Christian Fibiger, PhD - Independent Director Dr. Fibiger has held senior positions in biotechnology and pharmaceutical companies. Prior to serving as SVP and …See details»
Gaba Therapeutics, Inc - Employees, Contact info, Overview - Wiza
View info about Gaba Therapeutics, Inc (gabarx.com). Gaba Therapeutics, Inc is a company located in Newport Beach, California, United States. Find employees, official website, emails, …See details»
GABA Therapeutics Appoints Mario David Saltarelli M.D., Ph.D. as …
NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (“GABA”) a clinical-stage biotechnology company developing novel therapies for anxiety, …See details»
atai Life Sciences Company GABA Therapeutics Announces …
Jan 10, 2023 “According to a World Health Organization report, the number of people living with anxiety disorders globally grew from 298 million people in 2020 to 374 million in 2021,” said …See details»
Gaba Therapeutics - VentureRadar
Similar Companies: NiKang Therapeutics USA Privately Held NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule …See details»
GABA Therapeutics and ATAI Life Sciences Partner to Develop a …
Sep 20, 2019 For more detailed information on GABA Therapeutics, visit www.gabarx.com. About Anxiety. Anxiety, which is frequently comorbid with depression, is the largest mental …See details»
Our Science - gabarx.com
OUR SCIENCE Enhancing the Body’s Own Natural Neurosteroids to Combat Serious CNS Disorders GABA Therapeutics has focused its science on biological systems where …See details»
Understanding GABAergic synapse diversity and its implications …
A defining feature of the GABAergic system is its staggering complexity, which results from the enormous diversity of the cellular and molecular components that mediate GABAergic …See details»
atai Life Sciences Company GABA Therapeutics Announces …
Jan 9, 2023 atai Life Sciences. GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single …See details»
GRX-917 Pipeline – gabarx.com
GRX-917 PIPELINE The primary clinical development focus is getting GRX-917 approved in generalized anxiety disorder by 2028, since GAD is a derisked indication with large unmet …See details»